CVS HEALTH Corp: Form 10-Q for the period ended Mar 31, 2013
Filed with the SEC on May 1, 2013 and accepted by EDGAR at May 1, 2013, 16:41 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2013-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2013-01-01 to 2013-03-31 | $30.76bn | us-gaap:Revenues |
| Cost of revenue | 3 months2013-01-01 to 2013-03-31 | $25.18bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months2013-01-01 to 2013-03-31 | $5.58bn | us-gaap:GrossProfit |
| Operating income | 3 months2013-01-01 to 2013-03-31 | $1.70bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2013-01-01 to 2013-03-31 | $127.0m | us-gaap:InterestExpense |
| Income tax | 3 months2013-01-01 to 2013-03-31 | $617.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2013-01-01 to 2013-03-31 | $956.0m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2013-01-01 to 2013-03-31 | $0.77 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2013-01-01 to 2013-03-31 | $0.78 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2013-01-01 to 2013-03-31 | 1,241,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2013-01-01 to 2013-03-31 | $1.64bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2013-01-01 to 2013-03-31 | $318.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2013-01-01 to 2013-03-31 | $277.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 3 months2013-01-01 to 2013-03-31 | $393.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2013-03-31 | $1.55bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2013-03-31 | $19.73bn | us-gaap:AssetsCurrent |
| Total assets | At period end2013-03-31 | $66.07bn | us-gaap:Assets |
| Current liabilities | At period end2013-03-31 | $13.20bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2013-03-31 | $9.35bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2013-03-31 | $12.0m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | At period end2013-03-31 | $300.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2013-03-31 | $38.21bn | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Source: SEC EDGAR, the filing index for accession 0000064803-13-000005. Last ingested by Listed: Nov 6, 2026, 17:47 ET. Listed shows no prices and gives no investment advice.